Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The CONSORT (CONsolidated Standards Of Reporting Trials) 2010 statement is the standard guideline for reporting completed randomised trials. The CONSORT Dose-finding Extension (DEFINE) extends the guidance (with 21 new items and 19 modified items) to early phase dose-finding trials with interim dose escalation or de-escalation strategies. Such trials generally focus on safety, tolerability, activity, and recommending dosing and scheduling regimens for further clinical development. These trials are often inadequately reported, hampering their informativeness and making evidence informed decisions difficult. The CONSORT-DEFINE guidance aims to develop an international, consensus driven guideline for reporting early phase dose-finding trials to promote transparency, completeness, reproducibility, and facilitate the interpretation of the results. The CONSORT-DEFINE guidance provides recommendations for essential items that should be reported in early phase dose-finding trials to promote greater clarity, reproducibility, informativeness, and usefulness of results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffmann, T. C., Glasziou, P. P., Boutron, I., Milne, R., Perera, R., Moher, D., Altman, D. G., Barbour, V., Macdonald, H., Johnston, M., et al. (2014) · BMJ · doi:10.1136/bmj.g1687 · Cited by 10,548
Self-citationSPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363 · cited 1×
“We also developed a dose-finding extension for SPIRIT 2013, 46 SPIRIT-DEFINE, which has been reported elsewhere.”
Self-citationResearch guidelines for the Delphi survey technique
Hasson, F. (2000) · Journal of Advanced Nursing · doi:10.1046/j.1365-2648.2000.01567.x · Cited by 5,951
Diamond, I. R., Grant, R. C., Feldman, B. M., Pencharz, P. B., Ling, S. C., Moore, A. M., & Wales, P. W. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.12.002 · Cited by 3,740
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.004 · Cited by 1,858
Self-citationConsensus measurement in Delphi studies
von der Gracht, H. A. (2012) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2012.04.013 · Cited by 1,831
Estimation of clinical trial success rates and related parameters
Wong, C. H., Siah, K. W., & Lo, A. W. (2019) · Biostatistics · doi:10.1093/biostatistics/kxx069 · Cited by 1,585
Boutron, I., Altman, D. G., Moher, D., Schulz, K. F., Ravaud, P., & for the CONSORT NPT Group* (2017) · Annals of Internal Medicine · doi:10.7326/m17-0046 · Cited by 1,538 · cited 1×
“CONSORT extensions for non-pharmacological treatments and outcomes might also be relevant.”
Dose Escalation Methods in Phase I Cancer Clinical Trials
Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp079 · Cited by 867
Adaptive designs in clinical trials: why use them, and how to run and report them
Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., Holmes, J., Mander, A. P., Odondi, L., Sydes, M. R., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1017-7 · Cited by 829
Self-citation
Cited by
CONSORT 2025 statement: updated guideline for reporting randomised trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081123 · Cited by 1,195
Self-citationCONSORT 2025 statement: updated guideline for reporting randomised trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00672-5 · Cited by 510
Self-citationCONSORT 2025 Statement: Updated Guideline for Reporting Randomized Trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · JAMA · doi:10.1001/jama.2025.4347 · Cited by 369
Self-citationCONSORT 2025 statement: updated guideline for reporting randomized trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03635-5 · Cited by 283
Self-citationCONSORT 2025 statement: Updated guideline for reporting randomised trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · PLOS Medicine · doi:10.1371/journal.pmed.1004587 · Cited by 139
“…of extensions for trial designs include recommendations for adaptive designs [33], cluster trials [34], crossover trials [35], early phase trials [36], factorial trials [37], non-inferiority and equivalence trials [38], pragmatic trials [39], multi-arm trials [40], n-of-1 trials [41], pilot and…”
Self-citation
Metadata
- Authors
- Yap, C., Solovyeva, O., de Bono, J., Rekowski, J., Patel, D., Jaki, T., Mander, A., Evans, T. R. J., Peck, R., Hayward, K. S., Hopewell, S., Ursino, M., Rantell, K. R., Calvert, M., Lee, S., Kightley, A., Ashby, D., Chan, A.-W., Garrett-Mayer, E., Isaacs, J. D., Golub, R., Kholmanskikh, O., Richards, D., Boix, O., Matcham, J., Seymour, L., Ivy, S. P., Marshall, L. V., Hommais, A., Liu, R., Tanaka, Y., Berlin, J., Espinasse, A., Dimairo, M., & Weir, C. J.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2023-10-20
- Volume
- 383
- Pages
- e076387
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W4387807553
- Cited by
- 51
- References
- 16
- FWCI
- 10.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. https://app.cochat.ai/papers/10.1136/bmj-2023-076387
- The paper
- Yap, C., Solovyeva, O., de Bono, J., Rekowski, J., Patel, D., Jaki, T., Mander, A., Evans, T. R. J., Peck, R., Hayward, K. S., Hopewell, S., Ursino, M., Rantell, K. R., Calvert, M., Lee, S., Kightley, A., Ashby, D., Chan, A.-W., Garrett-Mayer, E., . . . Weir, C. J. (2023). Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance. BMJ. https://doi.org/10.1136/bmj-2023-076387
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.